文献速递胸部技术与安全CTMRPET

非小细胞肺癌免疫检查点抑制剂治疗的影像学表现

Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer.
PubMed 文献 · Radiographics · 2022-10-14

该综述总结了免疫检查点抑制剂(ICI)治疗非小细胞肺癌的基本原理、适应证、疗效评估标准及非典型反应模式(如假性进展),并系统描述了免疫相关不良事件(irAE)的影像学表现,强调需避免将其误判为转移、进展或感染。

要点

  • 熟悉假性进展等非典型反应模式,避免将初期肿瘤增大误判为进展。
  • 掌握irAE的影像谱(如肺炎、心肌炎、结肠炎),避免误诊为转移或感染。
  • irAE通常出现在治疗开始后数周至数月,阅片需结合治疗史。

核心结论

  • ICI可导致假性进展等非典型反应模式,需采用专用疗效标准评估。
  • irAE可累及多个器官,影像表现多样,需与转移、进展或感染鉴别。

研究设计与样本

  • 综述性文章,总结ICI治疗NSCLC的基本原理、适应证、疗效评估及irAE影像表现。
  • 文中提及美国FDA已批准多种ICI作为NSCLC一线治疗,但未报告具体研究样本量或中心数。

关键影像表现/征象

  • 假性进展表现为肿瘤负荷初期增大而后减小。
  • irAE包括脑炎、肺炎、心肌炎、肝炎和结肠炎等,影像上需与转移、进展或感染区分。

诊断标准与关键数值

  • 已针对接受免疫治疗的患者制定专门的疗效评估标准,原文未列出具体阈值或分级。

临床应用与阅片要点

  • 阅片时需了解患者是否接受ICI治疗,警惕假性进展,避免过早判定进展。
  • 发现肺炎、心肌炎、结肠炎等炎性改变时,应结合治疗史考虑irAE,避免误诊为转移或感染。

局限性

  • 本文为综述,未报告原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The normal immune system identifies and eliminates precancerous and cancerous cells. However, tumors can develop immune resistance mechanisms, one of which involves the exploitation of pathways, termed immune checkpoints, that normally suppress T-cell function. The goal of immune checkpoint inhibitor (ICI) immunotherapy is to boost T-cell-mediated immunity to mount a more effective attack on cancer cells. ICIs have changed the treatment landscape of advanced non-small cell lung cancer (NSCLC), and numerous ICIs have now been approved as first-line treatments for NSCLC by the U.S. Food and Drug Administration. ICIs can cause atypical response patterns such as pseudoprogression, whereby the tumor burden initially increases but then decreases. Therefore, response criteria have been developed specifically for patients receiving immunotherapy. Because ICIs activate the immune system, they can lead to inflammatory side effects, termed immune-related adverse events (irAEs). Usually occurring within weeks to months after the start of therapy, irAEs range from asymptomatic abnormal laboratory results to life-threatening conditions such as encephalitis, pneumonitis, myocarditis, hepatitis, and colitis. It is important to be aware of the imaging appearances of the various irAEs to avoid misinterpreting them as metastatic disease, progressive disease, or infection. The basic principles of ICI therapy; indications for ICI therapy in the setting of NSCLC; response assessment and atypical response patterns of ICI therapy, as compared with conventional chemotherapy; and the spectrum of irAEs seen at imaging are reviewed. An invited commentary by Nishino is available online. ©RSNA, 2022.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Shroff, Strange, Ahuja, et al. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer. Radiographics. 2022. PMID: 36240075. doi:10.1148/rg.220108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。